MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of MediciNova (NASDAQ:MNOV) in a report released on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

MediciNova Price Performance

NASDAQ MNOV opened at $1.83 on Friday. The company’s fifty day moving average is $1.83 and its two-hundred day moving average is $1.52. MediciNova has a 52-week low of $1.12 and a 52-week high of $2.55. The firm has a market capitalization of $89.52 million, a price-to-earnings ratio of -11.41 and a beta of 0.77.

MediciNova Company Profile

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.